Table 5 Comparisons of interleukin-6 and cfDNA levels according to severity and between survivors and non-survivors
From: IL-6 and cfDNA monitoring throughout COVID-19 hospitalization are accurate markers of its outcomes
Severe and Critical | Moderate | p | ||
|---|---|---|---|---|
CCDC scale | IL-6 (pg/mL) | 32.44 [5.84; 104.03] | 9.00 [2.76; 33.84] | < 0.001 |
cfDNA (ng/mL) | 9.44 [6.15; 20.19] | 6.21 [3.46; 10.44] | < 0.001 | |
WHO OS | IL-6 (pg/mL) | 32.44 [5.69; 99.94] | 9.00 [2.90; 33.14] | < 0.001 |
cfDNA (ng/mL) | 9.08 [5.54; 19.38] | 6.88 [3.61; 10.73] | 0.001 | |
Critical | Moderate and Severe | p | ||
|---|---|---|---|---|
CCDC scale | IL-6 (pg/mL) | 59.48 [21.37; 175.20] | 10.06 [3.10; 34.21] | < 0.001 |
cfDNA (ng/mL) | 14.11 [7.13; 22.67] | 7.01 [4.01; 10.93] | < 0.001 | |
Survivors | Non-survivors | p | ||
|---|---|---|---|---|
Total samples (n = 201) | IL-6 (pg/mL) | 11.14 [3.49; 39.23] n = 158 | 52.49 [21.37; 152.90] n = 43 | < 0.001 |
cfDNA (ng/mL) | 7.06 [4.12; 11.40] n = 158 | 14.98 [7.42; 25.74] n = 43 | < 0.001 | |
1st sample (n = 93) | IL-6 (pg/mL) | 25.91 [5.77; 51.55] n = 74 | 66.91 [38.38; 162.70] n = 19 | 0.001 |
cfDNA (ng/mL) | 6.87 [4.01; 10.81] n = 74 | 14.98 [7.73; 22.51] n = 19 | 0.002 | |